Highest-materiality recent filing
RevMed Q1 net loss $453.8M, daraxonrasib shows OS 13.2 mo in pancreatic cancer
Daraxonrasib Phase 3 RASolute 302: median OS 13.2 mo vs 6.7 mo chemo (HR 0.40); NDA submission planned.
Revolution Medicines issues $500M 0.50% convertible notes due 2033
Issued $500M 0.50% Convertible Senior Notes due 2033 under indenture with U.S. Bank Trust as trustee.
Revolution Medicines raises ~$2.15B via equity and convertible note offerings
Equity offering: 10,563,381 shares at $142/sh + full over-allotment of 1,584,506 shares; net proceeds ~$1.65B.
Revolution Medicines' daraxonrasib Phase 3 trial meets OS endpoint: 13.2 vs 6.7 months, HR 0.40
Phase 3 RASolute 302 trial: median OS 13.2 mo vs 6.7 mo for chemo (HR 0.40, p<0.0001); PFS also statistically significant.
Revolution Medicines FY2025 net loss $1.1B; daraxonrasib Phase 3 readout on track for H1 2026
Full year 2025 net loss $1.1B vs $600.1M in 2024; Q4 net loss $364.9M vs $194.6M.
Revolution Medicines Q3 net loss $305.2M; advancing daraxonrasib pivotal trials
Net loss $305.2M vs $156.3M YoY; R&D expense $262.5M (+73%), G&A $52.8M (+120%).
Daraxonrasib shows 35% ORR in 2L PDAC, 55% in 1L combo; Phase 3 planned
2L PDAC: ORR 29-35% (RAS G12X and broader mutant), DCR 92-95%, median PFS 8.1-8.5 mo, median OS 13.1-15.6 mo.
Revolution Medicines Q2 net loss $247.8M; advances Phase 3 RAS trials; $2B Royalty Pharma deal
Net loss $247.8M vs $133.2M YoY; R&D expenses rose to $224.1M; FY2025 net loss guidance $1.03B-$1.09B.
Revolution Medicines secures up to $2B financing from Royalty Pharma, withdraws cash runway guidance
Received $250M upfront from Royalty Pharma; up to $1.25B total synthetic royalty on daraxonrasib sales.
On June 18, 2025, Barbara Weber, M.D., communicated her decision to resign from the board of directors (the “Board”) of Revolution Medicines, Inc.
Max materiality 0.90 · Median 0.75 · Most common event earnings